• Michiko Sugiyama, Takahiro Hasebe, Hiroko Shimada, Hideki Takeuchi, Kyoko Shimizu, Michio Shimizu, Masanori Yasuda, Shigeto Ueda, Takashi Shigekawa, Akihiko Osaki, and Toshiaki Saeki.
• Department of Pathology, Saitama Medical University International Medical Center, Hidaka City, Saitama 350-1298, Japan; Department of Breast Oncology, Saitama Medical University International Medical Center, Hidaka City, Saitama 350-1298, Japan. Electronic address: michikos612@gmail.com.
• Hum. Pathol. 2015 Jun 1; 46 (6): 906-16.

AbstractWe previously reported that the number of mitotic and apoptotic figures in tumor cells in blood vessel tumor emboli had the greatest significant power for the accurate prediction of the outcome of patients with invasive ductal carcinoma of the breast. The purpose of the present study was to devise a grading system for blood vessel tumor emboli based on the mitotic and apoptotic figures of tumor cells in blood vessel tumor emboli, enabling accurate prediction of the outcome of patients with invasive ductal carcinoma of the breast. We classified 263 invasive ductal carcinomas into the following 3 grades according to the numbers of mitotic and apoptotic figures in tumor cells located in blood vessels within 1 high-power field: grade 0, no blood vessel invasion; grade 1, absence of mitotic figures and presence of any number of apoptotic figures, or 1 mitotic figure and 0 to 2 apoptotic figures; and grade 2, 1 mitotic figure and 3 or more apoptotic figures, or 2 or more mitotic figures and 1 or more apoptotic figures. Multivariate analyses with well-known prognostic factors demonstrated that grade 2 blood vessel tumor emboli significantly increased the hazard ratios for tumor recurrence independent of the nodal status, pathological TNM stage, hormone receptor status, or HER2 status. The presently reported grading system for blood vessel tumor emboli is the strongest histologic factor for accurate prediction of the outcome of patients with invasive ductal carcinoma of the breast. Copyright © 2015 Elsevier Inc. All rights reserved.

31 keywords...

hide…